A library of peptide research, organized by hub.
Five subject hubs: peptide science fundamentals, analytical quality, evidence standards, compound profiles by pathway, and regulatory science. Every article separates molecule-level evidence from product-level status.
Compound Research
Compound-by-compound reviews of evidence, mechanism, safety, and product identity.
Selank Research Update (2026): Human Evidence, Anxiolytic Research, and Regulatory Status
Selank is a synthetic tuftsin-derived peptide that has been investigated primarily in neurobiology and anxiety research. This review examines published evidence, separates mechanistic findings from clinical data, and summarizes the current regulatory landscape.
Read articlePT-141 (Bremelanotide) Research Update (2026): Human Evidence, Melanocortin Biology, and Regulatory Status
PT-141, also known as bremelanotide, is unusual among peptide therapeutics because it progressed from experimental melanocortin research to FDA approval for a specific clinical indication. This review distinguishes established evidence from ongoing investigation while examining the broader melanocortin research landscape.
Read articleMelanotan II Research Update (2026): Human Evidence, Melanocortin Biology, and Regulatory Status
Melanotan II is a synthetic melanocortin peptide that has been studied for pigmentation, melanocortin receptor biology, and related physiological pathways. This review examines published human, animal, and laboratory evidence while separating mechanistic findings from clinical conclusions.
Read articleThymosin Alpha-1 Research Update (2026): Human Clinical Evidence, Immunology, and Regulatory Status
Thymosin Alpha-1 is one of the most extensively studied immunomodulatory peptides in clinical medicine. Unlike many investigational peptides, it has decades of human research and regulatory approvals in several countries. This review examines the evidence hierarchy, distinguishes approved uses from investigational research, and summarizes where the science stands in 2026.
Read articleIpamorelin Research Update (2026): Human Evidence, Ghrelin Receptor Biology, and Regulatory Status
Ipamorelin is a selective growth hormone secretagogue investigated for its effects on endogenous growth hormone signaling. This review examines the current evidence, separates mechanistic biology from clinical data, and summarizes its regulatory status as of 2026.
Read articleEpitalon Research Update (2026): Telomeres, Longevity Science, and the Human Evidence Gap
Epitalon has become one of the most discussed peptides in longevity research due to its reported effects on telomerase and cellular aging pathways. This review examines the current evidence, separates mechanistic findings from clinical data, and evaluates where the science stands in 2026.
Read articleKPV Research Update (2026): Human Evidence, Anti-Inflammatory Mechanisms, and Regulatory Status
KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone that has attracted attention for its anti-inflammatory properties in experimental systems. This review examines current evidence, distinguishes mechanistic findings from human data, and summarizes the peptide's regulatory status as of 2026.
Read articleBPC-157 Research Update (2026): Human Evidence, Preclinical Data, and Regulatory Status
BPC-157 remains one of the most discussed experimental peptides in regenerative research, yet human evidence remains extremely limited. This review separates mechanistic promise from clinical evidence and examines where the science and regulation stand in 2026.
Read articleSNAP-8 and SNARE-Complex-Inspired Cosmetic Peptide Research
A mechanistic inspiration is not the same as equivalent target engagement or clinical performance.
Read articleL-Carnitine and the Mitochondrial Carnitine Shuttle
Established deficiency-related evidence does not generalize to every carnitine product or research question.
Read articleGlutathione Research: Redox Biology, Formulation, and Route Dependence
Reduced and oxidized glutathione, plus route and formulation, all change what a study can support.
Read articleNAD+ Research: Cofactor Biology vs Direct Administration Claims
Essential cofactor biology does not automatically validate every method of administering NAD+.
Read articleSLU-PP-332 Is Not a Peptide: ERR Agonism and Exercise-Mimetic Research
SLU-PP-332 should not be marketed as a peptide and exercise-mimetic language should be read as research shorthand.
Read article5-Amino-1MQ Is Not a Peptide: NNMT Inhibition and Preclinical Metabolic Research
Correctly classifying 5-Amino-1MQ as a small-molecule NNMT inhibitor is the first step toward responsible interpretation.
Read articleThymalin and the Problem of Poorly Defined Peptide Mixtures
Thymalin illustrates why a product name without composition data cannot inherit older literature.
Read articleTB-500 vs Thymosin Beta-4: Why the Names Cannot Be Used Interchangeably
TB-500 and thymosin beta-4 are routinely conflated, but only one has a confirmed sequence and a real literature base.
Read articleThymosin Alpha-1 and Immune Signaling Research
A chemically defined 28-amino-acid peptide with indication-specific evidence and jurisdictionally variable status.
Read articleLL-37 and the Dual Nature of Antimicrobial Peptide Signaling
LL-37 is a context-dependent host-defense peptide whose antimicrobial and inflammatory behaviors are tightly linked.
Read articleGHK-Cu: Copper Binding, Matrix Biology, and Route-Specific Evidence
GHK-Cu has a defined copper-binding chemistry and a route-specific evidence base that should not be merged into a single narrative.
Read articleDSIP Research: A Historical Peptide With an Uncertain Target
DSIP has accumulated decades of scattered findings without a validated receptor or reproducible clinical role.
Read articleSemax Research: Neurotrophic Signaling, Regional Literature, and Unanswered Questions
Semax is an ACTH-fragment analogue studied in neuroprotection and neurotrophic signaling, with a literature base that remains regionally concentrated and difficult to generalize.
Read articleSelank Research and the Difficulty of Validating Neurobehavioral Peptides
Selank is a tuftsin-derived peptide studied in stress, behavior, immune signaling, and gene expression, but independent validation remains limited.
Read articleEpitalon Research: Telomeres, Circadian Biology, and Evidence Gaps
Epitalon is a synthetic tetrapeptide associated with telomere, pineal, circadian, and aging claims, but the evidence base is limited and difficult to validate independently.
Read articleFOXO4-DRI and the Experimental Biology of Cellular Senescence
FOXO4-DRI is an experimental retro-inverso peptide designed to disrupt a protein interaction in senescent cells.
Read articleMOTS-c and Mitochondrial-to-Nuclear Signaling
MOTS-c is a mitochondrial-derived peptide studied as a signal connecting cellular stress, metabolism, and nuclear gene regulation.
Read articleMelanotan II: Broad Melanocortin Activity and Significant Safety Questions
Melanotan II is a nonselective melanocortin agonist whose broad receptor activity and unapproved marketplace use raise significant safety concerns.
Read articleBremelanotide and Central Melanocortin Signaling
Bremelanotide is a cyclic melanocortin receptor agonist with an FDA-approved product for a specific indication and a defined safety profile.
Read articleOxytocin Research Beyond the Headlines
Oxytocin has established reproductive physiology and approved obstetric use, but behavioral findings are more heterogeneous than popular summaries suggest.
Read articleKisspeptin and the Control of Reproductive Neuroendocrine Signaling
Kisspeptin is a central regulator of the hypothalamic-pituitary-gonadal axis and has meaningful human experimental evidence.
Read articleIGF-1 LR3 and the Challenge of Translating Growth-Signaling Research
IGF-1 LR3 is a modified analogue used in experimental systems, but approved recombinant IGF-1 evidence cannot be transferred to it automatically.
Read articleTesamorelin: A Defined GHRH Analogue With Established Human Research
Tesamorelin is a stabilized GHRH analogue with an FDA-approved finished product and a substantial human evidence base for a specific indication.
Read articleSermorelin and the Biology of GHRH(1-29)
Sermorelin is a synthetic version of the biologically active N-terminal segment of growth-hormone-releasing hormone.
Read articleIpamorelin and Ghrelin-Receptor Research
Ipamorelin is a synthetic growth-hormone secretagogue studied for agonism of the ghrelin receptor and stimulation of pituitary growth-hormone release.
Read articleCJC-1295, Mod GRF(1-29), and Why Product Identity Matters
CJC-1295 without DAC is often used as a marketplace label for chemically different materials, making sequence verification essential.
Read articleAOD-9604: From Growth-Hormone Fragment to Uncertain Research Candidate
AOD-9604 was designed from a growth-hormone fragment to investigate metabolic signaling without the full profile of intact growth hormone.
Read articleBPC-157 Research: What the Evidence Actually Shows
BPC-157 has a broad preclinical literature, but the gap between animal findings and credible human evidence remains substantial.
Read articleAmylin Biology and the Research Rationale for Cagrilintide
Cagrilintide is a long-acting amylin analogue developed to investigate satiety, gastric signaling, and combination pharmacology with incretin agents.
Read articleTriple-Receptor Agonism: What Retatrutide Research Is Testing
Retatrutide research asks whether one molecule can integrate GIP, GLP-1, and glucagon receptor signaling while maintaining an acceptable safety profile.
Read articleDual GIP/GLP-1 Receptor Agonism: The Science Behind Tirzepatide
Tirzepatide integrates GIP and GLP-1 receptor activity in one engineered peptide, creating a distinct pharmacologic profile rather than a simple stronger GLP-1 signal.
Read articleHow GLP-1 Receptor Agonism Is Studied in Metabolic Research
GLP-1 research spans receptor pharmacology, glucose-dependent endocrine signaling, gastric motility, central appetite pathways, and long-term clinical outcomes.
Read article